Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Qaiser Bashir; Kamal Chamoun; Denái R. Milton; Maliha Khan; Sairah Ahmed; Rohtesh Mehta; Uday R. Popat; Partow Kebriaei; Yago Nieto; Betul Oran; Stefan O. Ciurea; Chitra Hosing; Isa Khouri; Krina Patel; Elisabet E. Manasanch; Hans C. Lee; Robert Z. Orlowski; Richard E. Champlin; Muzaffar H. Qazilbash

doi:10.1080/10428194.2019.1633633

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Qaiser Bashir, Kamal Chamoun, Denái R. Milton, Maliha Khan, Sairah Ahmed, Rohtesh Mehta, Uday R. Popat, Partow Kebriaei, Yago Nieto, Betul Oran, Stefan O. Ciurea, Chitra Hosing, Isa Khouri, Krina Patel, Elisabet E. Manasanch, Hans C. Lee, Robert Z. Orlowski, Richard E. Champlin, Muzaffar H. Qazilbash

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

There is limited data on the outcomes of autologous hematopoietic cell transplantation (auto-HCT) in myeloma patients, 75 or older. We retrospectively analyzed all myeloma patients (n = 72), aged ≥75, who underwent auto-HCT at our center between January 1, 2000, and December 31, 2015. All patients received melphalan ≥140 mg m⁻² conditioning. At day-100, the cumulative incidence of non-relapse mortality was 1%. The overall response rate was 91% with 29% achieving complete/stringent complete remission. The median progression-free survival (PFS) was 31.4 months, and median overall survival (OS) was 72.8 months. The presence of high-risk cytogenetic abnormalities was associated with inferior PFS (p = 0.005) and OS (p = 0.005), while international staging system stage III was identified as a negative prognostic factor for OS (p = 0.002 vs. stage II). We conclude that auto-HCT can be safely performed in myeloma patients 75 and older and is associated with encouraging response rates.

Original language	English (US)
Pages (from-to)	3536-3543
Number of pages	8
Journal	Leukemia and Lymphoma
Volume	60
Issue number	14
DOIs	https://doi.org/10.1080/10428194.2019.1633633
State	Published - Dec 6 2019

Keywords

Clinical results
elderly
marrow and stem cell transpantation
myeloma
neoplasia

ASJC Scopus subject areas

Hematology
Oncology
Cancer Research

MD Anderson CCSG core facilities

Biostatistics Resource Group

Access to Document

10.1080/10428194.2019.1633633

Cite this

Bashir, Q., Chamoun, K., Milton, D. R., Khan, M., Ahmed, S., Mehta, R., Popat, U. R., Kebriaei, P., Nieto, Y., Oran, B., Ciurea, S. O., Hosing, C., Khouri, I., Patel, K., Manasanch, E. E., Lee, H. C., Orlowski, R. Z., Champlin, R. E., & Qazilbash, M. H. (2019). Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years. Leukemia and Lymphoma, 60(14), 3536-3543. https://doi.org/10.1080/10428194.2019.1633633

Bashir, Q, Chamoun, K, Milton, DR, Khan, M, Ahmed, S, Mehta, R, Popat, UR , Kebriaei, P , Nieto, Y , Oran, B, Ciurea, SO, Hosing, C , Khouri, I , Patel, K, Manasanch, EE, Lee, HC , Orlowski, RZ , Champlin, RE & Qazilbash, MH 2019, 'Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years', Leukemia and Lymphoma, vol. 60, no. 14, pp. 3536-3543. https://doi.org/10.1080/10428194.2019.1633633

@article{b0de03836643408e929168456b00df95,

title = "Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years",

abstract = "There is limited data on the outcomes of autologous hematopoietic cell transplantation (auto-HCT) in myeloma patients, 75 or older. We retrospectively analyzed all myeloma patients (n = 72), aged ≥75, who underwent auto-HCT at our center between January 1, 2000, and December 31, 2015. All patients received melphalan ≥140 mg m−2 conditioning. At day-100, the cumulative incidence of non-relapse mortality was 1%. The overall response rate was 91% with 29% achieving complete/stringent complete remission. The median progression-free survival (PFS) was 31.4 months, and median overall survival (OS) was 72.8 months. The presence of high-risk cytogenetic abnormalities was associated with inferior PFS (p = 0.005) and OS (p = 0.005), while international staging system stage III was identified as a negative prognostic factor for OS (p = 0.002 vs. stage II). We conclude that auto-HCT can be safely performed in myeloma patients 75 and older and is associated with encouraging response rates.",

keywords = "Clinical results, elderly, marrow and stem cell transpantation, myeloma, neoplasia",

author = "Qaiser Bashir and Kamal Chamoun and Milton, {Den{\'a}i R.} and Maliha Khan and Sairah Ahmed and Rohtesh Mehta and Popat, {Uday R.} and Partow Kebriaei and Yago Nieto and Betul Oran and Ciurea, {Stefan O.} and Chitra Hosing and Isa Khouri and Krina Patel and Manasanch, {Elisabet E.} and Lee, {Hans C.} and Orlowski, {Robert Z.} and Champlin, {Richard E.} and Qazilbash, {Muzaffar H.}",

note = "Publisher Copyright: {\textcopyright} 2019, {\textcopyright} 2019 Informa UK Limited, trading as Taylor & Francis Group.",

year = "2019",

month = dec,

day = "6",

doi = "10.1080/10428194.2019.1633633",

language = "English (US)",

volume = "60",

pages = "3536--3543",

journal = "Leukemia and Lymphoma",

issn = "1042-8194",

publisher = "Informa Healthcare",

number = "14",

}

TY - JOUR

T1 - Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

AU - Bashir, Qaiser

AU - Chamoun, Kamal

AU - Milton, Denái R.

AU - Khan, Maliha

AU - Ahmed, Sairah

AU - Mehta, Rohtesh

AU - Popat, Uday R.

AU - Kebriaei, Partow

AU - Nieto, Yago

AU - Oran, Betul

AU - Ciurea, Stefan O.

AU - Hosing, Chitra

AU - Khouri, Isa

AU - Patel, Krina

AU - Manasanch, Elisabet E.

AU - Lee, Hans C.

AU - Orlowski, Robert Z.

AU - Champlin, Richard E.

AU - Qazilbash, Muzaffar H.

PY - 2019/12/6

Y1 - 2019/12/6

N2 - There is limited data on the outcomes of autologous hematopoietic cell transplantation (auto-HCT) in myeloma patients, 75 or older. We retrospectively analyzed all myeloma patients (n = 72), aged ≥75, who underwent auto-HCT at our center between January 1, 2000, and December 31, 2015. All patients received melphalan ≥140 mg m−2 conditioning. At day-100, the cumulative incidence of non-relapse mortality was 1%. The overall response rate was 91% with 29% achieving complete/stringent complete remission. The median progression-free survival (PFS) was 31.4 months, and median overall survival (OS) was 72.8 months. The presence of high-risk cytogenetic abnormalities was associated with inferior PFS (p = 0.005) and OS (p = 0.005), while international staging system stage III was identified as a negative prognostic factor for OS (p = 0.002 vs. stage II). We conclude that auto-HCT can be safely performed in myeloma patients 75 and older and is associated with encouraging response rates.

AB - There is limited data on the outcomes of autologous hematopoietic cell transplantation (auto-HCT) in myeloma patients, 75 or older. We retrospectively analyzed all myeloma patients (n = 72), aged ≥75, who underwent auto-HCT at our center between January 1, 2000, and December 31, 2015. All patients received melphalan ≥140 mg m−2 conditioning. At day-100, the cumulative incidence of non-relapse mortality was 1%. The overall response rate was 91% with 29% achieving complete/stringent complete remission. The median progression-free survival (PFS) was 31.4 months, and median overall survival (OS) was 72.8 months. The presence of high-risk cytogenetic abnormalities was associated with inferior PFS (p = 0.005) and OS (p = 0.005), while international staging system stage III was identified as a negative prognostic factor for OS (p = 0.002 vs. stage II). We conclude that auto-HCT can be safely performed in myeloma patients 75 and older and is associated with encouraging response rates.

KW - Clinical results

KW - elderly

KW - marrow and stem cell transpantation

KW - myeloma

KW - neoplasia

UR - http://www.scopus.com/inward/record.url?scp=85068670982&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85068670982&partnerID=8YFLogxK

U2 - 10.1080/10428194.2019.1633633

DO - 10.1080/10428194.2019.1633633

M3 - Article

C2 - 31282244

AN - SCOPUS:85068670982

SN - 1042-8194

VL - 60

SP - 3536

EP - 3543

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

IS - 14

ER -

Outcomes of autologous hematopoietic cell transplantation in myeloma patients aged ≥75 years

Abstract

Keywords

ASJC Scopus subject areas

MD Anderson CCSG core facilities

Access to Document

Other files and links

Fingerprint

Cite this